Aktiekursudvikling
WntResearch: Closer Than Ever
Case: WntResearch Closer than ever WntResearch has applied for their phase II trials regarding proof-of-concept for the FOXT-5 compound. Hence, WntResearch is closer than ever
12. september 2018
Case: WntResearch Closer than ever WntResearch has applied for their phase II trials regarding proof-of-concept for the FOXT-5 compound. Hence, WntResearch is closer than ever
Kapital Partner udfører eller har inden for de seneste 12 måneder udført corporate finance, market relations, investor relations, Certified Adviser eller andre rådgivningsaktiviteter for følgende børsnoterede selskaber: CS Medica, EKOBOT AB, Biotech, Ensurge, Lifecare AS, NORD.investments, Biosergen, Hypefactors, Curasight, Re-Match, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.